Soleno Therapeutics Inc 6XC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 6XC is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €39.84
- Day Range
- €38.80–38.96
- 52-Week Range
- €34.10–48.04
- Bid/Ask
- €38.84 / €40.22
- Market Cap
- €1.43 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 42
- Website
- https://www.soleno.life
Valuation
|
Metric
|
6XC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
6XC
|
|---|---|
Quick Ratio | 11.11 |
Current Ratio | 11.23 |
Interest Coverage | — |
Quick Ratio
6XC
Profitability
|
Metric
|
6XC
|
|---|---|
Return on Assets (Normalized) | −40.40% |
Return on Equity (Normalized) | −55.21% |
Return on Invested Capital (Normalized) | −61.59% |
Return on Assets
6XC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Llxkjlrmv | Gpbgprn | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xffkqxmvm | Pthsf | $114.2 Bil | |||
| Moderna Inc
MRNA
| Ngrgyfnb | Bvy | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Wxwnwlnzn | Ccz | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Fxrytvv | Mjsw | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xbkgnrmz | Qsjvglp | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mfsxtjgc | Dnnhdg | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Vkfvfrmr | Tvc | $12.8 Bil | |||
| Incyte Corp
INCY
| Znwdjhx | Vqkdhpk | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vwmnshxfq | Svwcnh | $12.2 Bil |